TNGX icon

Tango Therapeutics

6.11 USD
+0.07
1.16%
At close Jul 10, 4:00 PM EDT
After hours
6.11
+0.00
0.00%
1 day
1.16%
5 days
6.45%
1 month
36.69%
3 months
370.00%
6 months
108.53%
Year to date
95.21%
1 year
-33.80%
5 years
-40.27%
10 years
-40.27%
 

About: Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Employees: 155

0
Funds holding %
of 7,312 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

8% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 39

0.15% more ownership

Funds ownership: 99.09% [Q4 2024] → 99.24% (+0.15%) [Q1 2025]

11% less funds holding

Funds holding: 137 [Q4 2024] → 122 (-15) [Q1 2025]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q4 2024] → 4 (-2) [Q1 2025]

47% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 30

55% less capital invested

Capital invested by funds: $329M [Q4 2024] → $147M (-$182M) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$13
113%
upside
Avg. target
$13
113%
upside
High target
$13
113%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Robert Burns
113%upside
$13
Buy
Reiterated
14 Apr 2025

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines' daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer.
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
Positive
Zacks Investment Research
2 weeks ago
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Neutral
GlobeNewsWire
1 month ago
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 3:20-3:55 PM ET.
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
Neutral
GlobeNewsWire
1 month ago
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in patients with MTAP-deleted solid tumors, with a focus on glioblastoma (GBM). TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor.
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
Negative
Zacks Investment Research
1 month ago
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.35 per share a year ago.
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend –   BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2025, and provided business highlights. “Accumulating data continue to support TNG462 as the potential best-in-class PRMT5 inhibitor,” said Barbara Weber, M.D.
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
Negative
Zacks Investment Research
2 months ago
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Neutral
GlobeNewsWire
2 months ago
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
Neutral
GlobeNewsWire
3 months ago
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
Negative
Zacks Investment Research
4 months ago
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.32 per share a year ago.
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Charts implemented using Lightweight Charts™